Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Psoriatic arthritis (PsA) patients who also qualified for a diagnosis of metabolic syndrome were far more likely to meet ...

APEX shows Tremfya is the first IL-23 inhibitor to slow joint damage in psoriatic arthritis, offering early, multi-domain ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...